Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Phocas Financial Corp.

Phocas Financial Corp. grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 31.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,330,413 shares of the company's stock after acquiring an additional 315,223 shares during the period. Amneal Pharmaceuticals comprises about 1.4% of Phocas Financial Corp.'s investment portfolio, making the stock its 16th biggest holding. Phocas Financial Corp. owned approximately 0.43% of Amneal Pharmaceuticals worth $10,537,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of AMRX. Barclays PLC increased its position in shares of Amneal Pharmaceuticals by 134.1% during the third quarter. Barclays PLC now owns 296,384 shares of the company's stock worth $2,466,000 after acquiring an additional 169,756 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Amneal Pharmaceuticals by 16.7% during the fourth quarter. SG Americas Securities LLC now owns 74,518 shares of the company's stock worth $590,000 after acquiring an additional 10,674 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth about $121,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in shares of Amneal Pharmaceuticals by 13.6% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company's stock worth $366,000 after acquiring an additional 5,523 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth about $520,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX traded up $0.07 during mid-day trading on Friday, reaching $7.37. The stock had a trading volume of 1,424,289 shares, compared to its average volume of 1,441,490. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -10.84 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 1-year low of $6.29 and a 1-year high of $9.48. The stock's 50 day simple moving average is $7.47 and its two-hundred day simple moving average is $8.00.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Analyst Ratings Changes

AMRX has been the subject of a number of research reports. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays lifted their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. Finally, Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $11.50.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the transaction, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the transaction, the director now owns 1,808,886 shares of the company's stock, valued at approximately $16,099,085.40. The trade was a 4.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.45% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.